Did You Know...
...that when IBM conducted a market study of Chester Carlson's invention in 1959, the company concluded that it would take only 5000 units of his new product to saturate the market? IBM therefore declined to be part of the new product introduction. Too bad for IBM. Carlson's invention was the xerography process, and his new product was the beginning of the Xerox Corporation. It is estimated that every day, worldwide, 3,000,000,000 copies are made!!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7432067 | Methods of detection of MATER protein autoantibodies Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater cDNA and protein sequences are provided. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not pr... | 10/07/2008 |
| 7374763 | Protein sequences containing antigenized antibodies for foot-and-mouth disease Protein sequences encoding antigenized antibodies for treatment of foot-and-mouth disease (FMD) or foot-and-mouth disease virus (FMDV) of swine is provided. The antigenized antibodies are created from the grafting of peptide epitopes derived from FMDV into swine ant... | 05/20/2008 |
| 7361742 | Methods and materials for treating inflammatory conditions The invention provides methods and materials for treating inflammatory conditions. Specifically, the invention provides polypeptides, isolated nucleic acids, host cells, and methods that can be used to induce an antibody response in a mammal against an antigen such ... | 04/22/2008 |
| 7358229 | Deuterated cyclosporin analogs and their use as immunomodulating agents Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical a... | 04/15/2008 |
| 7351570 | HDV nucleic acid molecules and applications thereof The invention concerns nucleic acid molecules derived from novel hepatitis D virus strains or isolates constituting genotypes different from known I, II and III genotypes, their fragments, corresponding proteins and their uses as diagnostic reagents. The invention a... | 04/01/2008 |
| 7332472 | Cyclosporine analogue mixtures and their use as immunomodulating agents The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known c... | 02/19/2008 |
| 7329410 | Compositions and method for WT1 specific immunotherapy A method for enhancing or inducing an immune response to WT1 is disclosed. In particular, the method comprises administering to a patient an immunogenic composition comprising an isolated polypeptide consisting of amino acids 1-249 of WT1 and a non-specific immune r... | 02/12/2008 |
| 7326769 | Method for isolating and purifying grass pollen allergens The invention relates to a method for quickly and effectively isolating and purifying five, namely the group 1, 2, 3, 10 and 13 allergens from grass pollen. The purification of said grass pollen is based on the inventive combination of hydrophobic interaction chroma... | 02/05/2008 |
| 7323181 | Compositions and methods for WT1 specific immunotherapy Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that sp... | 01/29/2008 |
| 7279172 | Treatment of autoimmune conditions with copolymer 1 and related copolymers The present invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolym... | 10/09/2007 |
| 7270827 | Multivalent streptococcal vaccine compositions and methods for use Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nu... | 09/18/2007 |
| 7256265 | Streptococcal C5a peptidase vaccine Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mamm... | 08/14/2007 |
| 7226603 | HBV core antigen particles with multiple immunogenic components attached via peptide ligands This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related struct... | 06/05/2007 |
| 7211408 | Recombitope peptides The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferab... | 05/01/2007 |
| 7204991 | Porphyromonas gingivalis recombinant proteins and truncations The present invention relates to soluble P. gingivalis polypeptides derived from PG32 and PG33 and to polynucleotides encoding these polypeptides. The P. gingivalis polypeptides and nucleotides can be used in compositions for use in raising an immune r... | 04/17/2007 |
| 7173108 | Peptide epitopes recognized by disease promoting CD4+ T lymphocytes The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includ... | 02/06/2007 |
| 7157091 | MAGE-A1 peptides presented by HLA class II molecules The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0–10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal co... | 01/02/2007 |
| 7144581 | Compositions and methods for WT1 specific immunotherapy Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that sp... | 12/05/2006 |
| 7135282 | Viral particles with exogenous internal epitopes The present invention relates to the expression of peptides on viral particles, and more particularly to the expression of peptides on the interior or the viral capsid. Methods are described for modifying viruses so that exogenous epitopes are expressed on the inter... | 11/14/2006 |
| 7118757 | Meningococcal class 1 outer-membrane protein vaccine Outer-membrane vesicles, Class 1 outer membrane proteins of Neisseria meningitidis, fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease. ... | 10/10/2006 |
| 7101562 | Conjugate vaccines for the prevention of dental caries The present invention provides glucan-based compositions and methods for stimulating an immune response against mutans streptococci components and vaccines and methods for the treatment and prevention of dental caries. In a preferred embodiment, a glucan polymer, pr... | 09/05/2006 |
| 7098303 | Conserved motif of hepatitis C virus E2/NS1 region Immunogenic polypeptides comprising hepatitis C virus (HCV) immunogens are described. The HCV immunogen comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-P he-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SE... | 08/29/2006 |
| 7097965 | Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary toxin protective antigen and the antigen, which is bound to a binary toxin protective antigen binding protei... | 08/29/2006 |
| 7074894 | Antigen composition against mycoplasma An isolated antigen against a Mycoplasma, prepared by a method including providing a sample of a Mycoplasma and an antibody probe, probing the Mycoplasma sample with the antibody probe to detect at least one antigen, and isolating the antigen de... | 07/11/2006 |
| 7074416 | Antigen of hybrid M protein and carrier for group A streptococcal vaccine Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes which encode the antigen are provided. Vaccine compositions and methods of administ... | 07/11/2006 |
| 7067247 | Hepatitis B virus surface protein We isolated and characterized a new surface mutant of the hepatitis B virus surface antigen (HBsAg). The mutant was isolated from a symptomatic patient with Down's syndrome who was found to be persistently positive for both for HBsAg and anti-HBs Antibody (Ab) with ... | 06/27/2006 |
| 7067138 | Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have ... | 06/27/2006 |
| 7018636 | Vaccine against Gram-negative bacterial infections A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LP... | 03/28/2006 |
| 6998385 | Cyclosporine analogue mixtures and their use as immunomodulating agents The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known c... | 02/14/2006 |
| 6955891 | Reagents for assaying Bacillus anthracis lethal factor protease The present invention features a Bacillus anthracis lethal factor substrate. The substrate can be used for example to measure lethal factor activity. Preferred substrates contain one or mare detectable labels and have a sufficiently high turnover rate for app... | 10/18/2005 |
| 6926896 | Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put t... | 08/09/2005 |
| 6906169 | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide The present invention relates to a composition comprsing a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid β (A... | 06/14/2005 |
| 6903184 | Multiple antigenic peptides immunogenic against Streptococcus pneumonia The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucl... | 06/07/2005 |
| 6881821 | Hepatitis-C virus type 4, 5, and 6 Newly elucidated sequences of hepatitis C virus type 4 and type 5 are described, together with those of a newly discovered type 6. Unique type-specific sequences in the NS4, NS5 and core regions enable HCV detection and genotyping into types 1 to 6. Antigenic peptid... | 04/19/2005 |
| 6855321 | Polyepitope carrier protein The invention relates to polyepitope carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. The... | 02/15/2005 |
| 6844423 | Compositions and methods for regulating bacterial pathogenesis The production of a purified extracellular bacterial signal called autoinducer-2 is regulated by changes in environmental conditions associated with a shift from a free-living existence to a colonizing or pathogenic existence in a host organism. Autoinducer-2 stimul... | 01/18/2005 |
| 6780420 | Carrier protein having an adjuvant effect, immunogenic complex containing it, process for their preparation, nucleotide sequence and vaccine The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80%... | 08/24/2004 |
| 6770281 | B-cell epitope peptides of HSP 65 The invention is directed to a peptide, comprising the amino acid sequence substantially as denoted by SEQ ID NO:1 and biologically functional homologues and derivatives thereof. ... | 08/03/2004 |
| 6756477 | Compositions and methods for the therapy and diagnosis of breast cancer Compositions and methods for the therapy and diagnosis of cancer, such as breast cancer, are disclosed. Compositions may comprise one or more breast tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeu... | 06/29/2004 |
| 6696061 | Immunomodulatory peptides A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human... | 02/24/2004 |
